Advertisement

Lung Cancer

First-Line Nivolumab Alone and Combined With Platinum-Based Chemotherapy in Advanced NSCLC

The phase I CheckMate 012 study examined the effects of nivolumab monotherapy and nivolumab combined with platinum-based doublets as first-line treatments in patients with...

Issues in Oncology

ASCO and AACI Initiative to Reduce Administrative and Regulatory Burden in Cancer Clinical Trials

As reported in the Journal of Clinical OncologyJulie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, Omaha, and colleagues have provided...

Head and Neck Cancer

Testosterone Therapy May Be Cardioprotective in Patients Undergoing Chemotherapy

The anabolic hormone testosterone may lessen the early adverse cardiovascular effects of chemotherapy and chemoradiation for advanced or recurrent cancer, according to a randomized...


Advertisement

More Top Stories

Pain Management
Global Cancer Care
Palliative Care

James F. Cleary, MD, on Global Access to Opioids

Lymphoma

Nivolumab Achieves Response in Most Patients With Classical Hodgkin Lymphoma After ASCT and Brentuximab Vedotin

In a phase II trial reported in The Lancet Oncology by Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, treatment with the anti–PD-1 (programmed cell death protein 1) immune checkpoint inhibitor nivolumab (Opdivo) produced response in two-thirds of patients with...

Advertisement

Nonwhite Organ Transplant Recipients Also at Heightened Risk for Skin Cancer

A new study from Drexel University College of Medicine suggests all organ transplant recipients, regardless of race, should receive routine, total-body screenings for skin cancer.

Out of 259 nonwhite transplant recipients who were evaluated in the study, 19 skin cancer lesions were identified in...

Solid Tumors

John D. Hainsworth, MD, on Advanced Solid Tumors: Results From the MyPathway Trial

Issues in Oncology
Lymphoma
Solid Tumors

Media Reports of Dramatic Responses to Immunotherapy After All Else Fails May Prompt Patients to Seek It Out

Immunotherapy has received “a lot of attention, mainly because of the media coverage,” Anas Younes, MD, medical oncologist and Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, said in an interview with The ASCO Post. “Many patients inquire, not about a specific ...

Head and Neck Cancer

Good Showing for Trastuzumab/Docetaxel Combination Against Salivary Gland Carcinoma

The combination of trastuzumab (Herceptin) and docetaxel seems to be highly active in patients with unresectable advanced HER2-positive salivary gland carcinoma of the ductal subtype, according to interim data from an open-label, single-arm phase II trial.1 More than two-thirds of patients had a...

High-Calcium, Low-Lactose Diet May Reduce Risk of Ovarian Cancer in African American Women

Research from Rutgers Cancer Institute of New Jersey and and other U.S. health and academic institutions shows a diet high in calcium and low in lactose may reduce the risk of ovarian cancer in African American women. The work, published by Qin et al in the British Journal of Cancer, also found sun ...

Lymphoma

David G. Maloney, MD, PhD, on Lymphomas: Treatment With CAR T Cells

The Best Oncology Lesson

I was 2 months into my first-year fellowship at Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, when I learned the best oncology lesson of my career. I owned a copy of DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology and had read Cancer Treatment...

Advertisement

Comparison of Second-Line Treatments in Advanced Pancreatic Cancer After Gemcitabine-Based Chemotherapy

In the Canadian phase III PANCREOX trial reported in the Journal of Clinical Oncology, Gill et al found no benefit of modified FOLFOX6 (infusional fluorouracil [5-FU], leucovorin, and oxaliplatin) vs infusional 5-FU/leucovorin as second-line treatment in patients with advanced pancreatic cancer who ...


click me